Network Meta-analysis of 1.5% Ruxolitinib Cream Versus Systemic Agents in the Treatment of Moderate Atopic Dermatitis
For patients with moderate AD who are eligible for systemic therapies, 1.5% ruxolitinib cream might provide disease control comparable to systemic treatments, such as dupilumab, regarding IGA 0/1, EASI-75, and Itch NRS4.
Authors
- Melinda Gooderham (ORCID: https://orcid.org/0000-0001-8926-0113)
- Ali Mojebi (ORCID: https://orcid.org/0000-0003-2318-8627)
- Becky Hooper (ORCID: https://orcid.org/0000-0002-0146-5577)
- M.H. Larbi
- Chih-ho Hong (ORCID: https://orcid.org/0000-0001-9963-8319)
- Ronald V. Marino (ORCID: https://orcid.org/0000-0003-2409-6812)
- Luis Miguel Pastor (ORCID: https://orcid.org/0000-0001-6067-2413)
- Grace Lai–Hung Wong (ORCID: https://orcid.org/0000-0002-2863-9389)
- Avery Hughes-Martin
- Di Wang (ORCID: https://orcid.org/0000-0002-6221-0949)
- Ping Wu (ORCID: https://orcid.org/0000-0002-0788-6268)
- A. Pepper
- H. Cameron
- Marie-Lise Dion
Institutions
- University of British Columbia (CA)
- SKiN Health (CA)
- MD Precision (Canada) (CA)
- EVERSANA (Canada) (CA)
- Incyte (United States) (US)
Publication Details
- Journal
- Dermatology and Therapy
- Published
- 2025-09-04
- DOI
- https://doi.org/10.1007/s13555-025-01503-1
- Citations
- 1
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 2.00
Funders
- Incyte